Intratumoral injection of R848 and poly(I:C) synergistically promoted antitumor immune responses by reprogramming macrophage polarization and activating DCs in lung cancer
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxae110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Shuanghui Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Guizhou University, Guiyang, China. Hauptthemen laut MEDLINE: Poly I-C, Dendritic Cells, Lung Neoplasms, Imidazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Key Laboratory of Respiratory Diseases, Guizhou Provincial Science and Technology Projects.
Abstract (Originalsprache)
Introduction
Immunotherapy has rapidly become a primary treatment option for many lung cancer patients because of its success in treating this prevalent and deadly disease. However, the success of immunotherapy relies on overcoming the immunosuppressive tumor microenvironment, making remodeling this environment a potential strategy for lung cancer therapy. Research suggests that Toll-like receptor (TLR) agonists can impede tumor growth by promoting the conversion of tumor-associated macrophages into an M1-like state or enhancing dendritic cell development. However, there is insufficient research on the combined use of TLR agonists for treating lung cancer.
Methods
In this study, we examined how TLR agonists such as resiquimod (R848) and poly(I:C) impact lung cancer treatment when used alone or in combination. In vitro, the regulatory functions and mechanisms of R848 and poly(I:C) were analyzed in primary macrophages, RAW264.7 cells, and primary dendritic cells (DCs). Tumor treatment efficacy was assessed in vivo with a Lewis lung carcinoma (LLC) mouse model.
Results
The combination of R848 + poly(I:C) enhances the transformation of macrophages from the M2 phenotype to the M1 phenotype by increasing inflammatory cytokine levels. The percentage of mature DCs expressing MHC-II+CD11c+ and CD86+ cells was significantly higher in the R848 + poly(I:C) group compared with the other groups. Intratumoral injection of the synergistic combination of R848 + poly(I:C) suppressed tumor growth by increasing the M1:M2 ratio in TAMs, activating DCs, and attracting CD4+ and CD8+ T cells.
Conclusion
R848 + poly(I:C) synergistically induces M1-like polarization of macrophages, activates DCs, and promotes effective antitumor immunity in mice with subcutaneous LLC tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Guizhou University, Guiyang, China.
- School of Basic Medical Sciences, Zunyi Medical University, Zunyi, China.
- NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, China.
ORCID-Profile: Shuanghui Chen
Förderung
- National Natural Science Foundation of China
- National Key Laboratory of Respiratory Diseases
- Guizhou Provincial Science and Technology Projects
- Guizhou Immunotherapy Research Talent Base
- Central Research Institute Fund of Chinese Academy of Medical Sciences
Zitieren
APA
Chen, S., Li, L., Yuan, H., Gui, H., Wan, Q., Wang, M., Lv, H., Wang, C., Zhu, L., Nie, Y., & Zhang, X. (2025). Intratumoral injection of R848 and poly(I:C) synergistically promoted antitumor immune responses by reprogramming macrophage polarization and activating DCs in lung cancer. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae110
Vancouver
Chen S, Li L, Yuan H, Gui H, Wan Q, Wang M, et al. Intratumoral injection of R848 and poly(I:C) synergistically promoted antitumor immune responses by reprogramming macrophage polarization and activating DCs in lung cancer. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae110
BibTeX
@article{Chen2025,
author = {Chen, Shuanghui and Li, Linzhao and Yuan, Haohua and Gui, Huan and Wan, Quan and Wang, Mengjiao and Lv, Hang and Wang, Chenglv and Zhu, Lan and Nie, Yingjie and Zhang, Xiangyan},
title = {Intratumoral injection of R848 and poly(I:C) synergistically promoted antitumor immune responses by reprogramming macrophage polarization and activating DCs in lung cancer},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxae110}
}
EUVIMED